{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T16:17:52Z","timestamp":1789661872254,"version":"4.0.1"},"reference-count":32,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annales Pharmaceutiques Fran\u00e7aises"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.pharma.2025.05.002","type":"journal-article","created":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T10:51:51Z","timestamp":1747219911000},"page":"941-953","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["ICH-Q3D based elemental impurities study in an oral drug product: Risk assessment according to the component approach (option 2b) confirmed by the finished product analysis (option 3)"],"prefix":"10.1016","volume":"83","author":[{"given":"Ayoub","family":"Hamidallah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Yafout","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibrahim","family":"Sbai El Otmani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.pharma.2025.05.002_bib0165","doi-asserted-by":"crossref","first-page":"60","DOI":"10.2478\/intox-2014-0009","article-title":"Toxicity, mechanism and health effects of some heavy metals","volume":"7","author":"Jaishankar","year":"2014","journal-title":"Interdiscip Toxicol"},{"key":"10.1016\/j.pharma.2025.05.002_bib0170","doi-asserted-by":"crossref","DOI":"10.1016\/j.fct.2015.10.006","article-title":"Toxic trace elements at gastrointestinal level","volume":"86","author":"Vazquez","year":"2015","journal-title":"Food Chem Toxicol"},{"key":"10.1016\/j.pharma.2025.05.002_bib0175","doi-asserted-by":"crossref","first-page":"104435","DOI":"10.1016\/j.yrtph.2019.104435","article-title":"Elemental impurities in pharmaceutical products adding fuel to the fire","volume":"108","author":"Maithani","year":"2019","journal-title":"Regul Toxicol Pharmacol"},{"issue":"5","key":"10.1016\/j.pharma.2025.05.002_bib0180","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1007\/s11095-010-0080-3","article-title":"USP Metal Impurities Advisory Panel. Metal impurities in food and drugs","volume":"27","author":"Abernethy","year":"2010","journal-title":"Pharm Res"},{"issue":"5","key":"10.1016\/j.pharma.2025.05.002_bib0185","first-page":"14","article-title":"From heavy metals testing to the measurement of elemental impurities in pharmaceuticals: Over 100 years in making the change","volume":"33","author":"DeStefano","year":"2018","journal-title":"Spectroscopy"},{"key":"10.1016\/j.pharma.2025.05.002_bib0190","series-title":"Guideline for Elemental Impurities Q3D(R2)","year":"2022"},{"key":"10.1016\/j.pharma.2025.05.002_bib0195","doi-asserted-by":"crossref","first-page":"4547","DOI":"10.1007\/s00216-016-9471-6","article-title":"Determination of elemental impurities in pharmaceutical products and related matrices by ICP-based methods: a review","volume":"408","author":"Barin","year":"2016","journal-title":"Anal Bioanal Chem"},{"issue":"5","key":"10.1016\/j.pharma.2025.05.002_bib0200","article-title":"The status of elemental impurities over a decade: a review","volume":"3","author":"Manthan Trivedi","year":"2019","journal-title":"Acta Sci Pharmaceut Sci"},{"key":"10.1016\/j.pharma.2025.05.002_bib0205","unstructured":"The United States Pharmacopeia, Chapter 232: Elemental Impurities\u2013Limits."},{"key":"10.1016\/j.pharma.2025.05.002_bib0210","unstructured":"The Europeen Pharmacopeia, 11ed, 5.20. Eemental Impurities."},{"issue":"4","key":"10.1016\/j.pharma.2025.05.002_bib0215","first-page":"78","article-title":"Metal leachables in therapeutic biologic products: origin, impact and detection","volume":"13","author":"Zhou","year":"2010","journal-title":"Am Pharm Rev"},{"issue":"1","key":"10.1016\/j.pharma.2025.05.002_bib0220","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5731\/pdajpst.2015.01005","article-title":"Materials in manufacturing and packaging systems as sources of elemental impurities in packaged drug products: a literature review","volume":"69","author":"Jenke","year":"2015","journal-title":"PDA J Pharm Sci Technol"},{"issue":"3","key":"10.1016\/j.pharma.2025.05.002_bib0225","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1080\/03639045.2020.1724136","article-title":"ICH Q3D based elemental impurities study in liquid pharmaceutical dosage form with high daily intake - comparative analysis by ICP-OES and ICP-MS","volume":"46","author":"Janchevska","year":"2020","journal-title":"Drug Dev Ind Pharm"},{"key":"10.1016\/j.pharma.2025.05.002_bib0230","doi-asserted-by":"crossref","first-page":"106689","DOI":"10.1016\/j.sab.2023.106689","article-title":"Analytical approach of elemental impurities in pharmaceutical products: a worldwide review","volume":"205","author":"Magalh\u00e3es Aleluia","year":"2023","journal-title":"Spectrochim Acta B Atomic Spectrosc"},{"key":"10.1016\/j.pharma.2025.05.002_bib0235","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.trac.2017.09.011","article-title":"Impact and practicability of recently introduced requirements on elemental impurities","volume":"101","author":"Pohl","year":"2018","journal-title":"Trends Anal Chem"},{"issue":"3","key":"10.1016\/j.pharma.2025.05.002_bib0240","first-page":"12","article-title":"Implementation of ICH Q3D elemental impurities guideline: challenges and opportunities","volume":"27","author":"Teasdale","year":"2015","journal-title":"Pharm Technol Eur"},{"issue":"3","key":"10.1016\/j.pharma.2025.05.002_bib0245","doi-asserted-by":"crossref","first-page":"197","DOI":"10.5731\/pdajpst.2021.012655","article-title":"Determination of ICH-Q3D elemental impurity leachables in glass vials by inductively coupled plasma mass spectrometry","volume":"77","author":"Breckenridge","year":"2023","journal-title":"PDA J Pharm Sci Technol"},{"issue":"1","key":"10.1016\/j.pharma.2025.05.002_bib0250","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1208\/s12249-011-9592-3","article-title":"Biologics formulations factors affecting metal leachables from stainless steel","volume":"12","author":"Zhou","year":"2011","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.pharma.2025.05.002_bib0255","unstructured":"United Stated Pharmacopoeia: Elemental Impurities\u2013Procedures <233>."},{"key":"10.1016\/j.pharma.2025.05.002_bib0260","unstructured":"The Europeen Pharmacopeia, 11ed, 2.4.20. Determination Of Eemental Impurities."},{"key":"10.1016\/j.pharma.2025.05.002_bib0265","article-title":"An overview of sample preparation procedures for determination of elemental impurities in medicines","volume":"175","author":"Fernanda","year":"2022","journal-title":"Microchemical J"},{"key":"10.1016\/j.pharma.2025.05.002_bib0270","series-title":"Validation of Analytical Procedures Q2 (R2)","year":"2022"},{"issue":"12","key":"10.1016\/j.pharma.2025.05.002_bib0275","doi-asserted-by":"crossref","first-page":"4197","DOI":"10.1002\/jps.24650","article-title":"Elemental impurities in pharmaceutical excipients","volume":"104","author":"Li","year":"2015","journal-title":"J Pharm Sci"},{"issue":"5","key":"10.1016\/j.pharma.2025.05.002_bib0280","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1016\/j.xphs.2021.10.012","article-title":"ICH Q3D drug product elemental risk assessment: the use of an elemental impurities excipients database","volume":"111","author":"Torres","year":"2022","journal-title":"J Pharm Sci"},{"issue":"17","key":"10.1016\/j.pharma.2025.05.002_bib0285","doi-asserted-by":"crossref","first-page":"4547","DOI":"10.1007\/s00216-016-9471-6","article-title":"Determination of elemental impurities in pharmaceutical products and related matrices by ICP-based methods: a review","volume":"408","author":"Barin","year":"2016","journal-title":"Anal Bioanal Chem"},{"issue":"3","key":"10.1016\/j.pharma.2025.05.002_bib0290","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1080\/03639045.2020.1724136","article-title":"ICH Q3D based elemental impurities study in liquid pharmaceutical dosage form with high daily intake - comparative analysis by ICP-OES and ICP-MS","volume":"46","author":"Janchevska","year":"2020","journal-title":"Drug Dev Ind Pharm"},{"key":"10.1016\/j.pharma.2025.05.002_bib0295","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.trac.2016.02.001","article-title":"Recent advances in the determination of elemental impurities in pharmaceuticals\u2013Status, challenges and moving frontiers","volume":"80","author":"Balaram","year":"2016","journal-title":"Trends Anal Chem"},{"key":"10.1016\/j.pharma.2025.05.002_bib0300","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.jpba.2017.06.045","article-title":"Development and validation of an ICP-MS method for the determination of elemental impurities in TP-6076 active pharmaceutical ingredient (API) according to USP 232<232>\/<233>","volume":"145","author":"Chahrour","year":"2017","journal-title":"J Pharm Biomed Anal"},{"issue":"1","key":"10.1016\/j.pharma.2025.05.002_bib0305","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1177\/14690667231211696","article-title":"Method for determination of elemental impurities in metronidazole benzoate using inductively coupled plasma mass spectrometry","volume":"30","author":"Tian","year":"2024","journal-title":"Eur J Mass Spectrom (Chichester, Eng)"},{"issue":"3","key":"10.1016\/j.pharma.2025.05.002_bib0310","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1080\/03639045.2020.1724136","article-title":"ICH Q3D based elemental impurities study in liquid pharmaceutical dosage form with high daily intake - comparative analysis by ICP-OES and ICP-MS","volume":"46","author":"Janchevska","year":"2020","journal-title":"Drug Dev Ind Pharm"},{"issue":"5","key":"10.1016\/j.pharma.2025.05.002_bib0315","doi-asserted-by":"crossref","first-page":"227","DOI":"10.5582\/ddt.2021.01078","article-title":"Study of the compatibility of oral magnesium oxide preparations sold in Japan with the ICH-Q3D guideline for elemental impurities","volume":"15","author":"Satoh","year":"2021","journal-title":"Drug Discov Ther"},{"issue":"2","key":"10.1016\/j.pharma.2025.05.002_bib0320","doi-asserted-by":"crossref","first-page":"e03359","DOI":"10.1016\/j.heliyon.2020.e03359","article-title":"Elemental impurities analysis in name-brand and generic omeprazole drug samples","volume":"6","author":"Pinheiro","year":"2020","journal-title":"Heliyon"}],"container-title":["Annales Pharmaceutiques Fran\u00e7aises"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000345092500080X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000345092500080X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T08:45:19Z","timestamp":1755765919000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S000345092500080X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":32,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S000345092500080X"],"URL":"https:\/\/doi.org\/10.1016\/j.pharma.2025.05.002","relation":{},"ISSN":["0003-4509"],"issn-type":[{"value":"0003-4509","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"ICH-Q3D based elemental impurities study in an oral drug product: Risk assessment according to the component approach (option 2b) confirmed by the finished product analysis (option 3)","name":"articletitle","label":"Article Title"},{"value":"Annales Pharmaceutiques Fran\u00e7aises","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharma.2025.05.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Acad\u00e9mie Nationale de Pharmacie. Published by Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}